Modus Therapeutics Secures Bridge Financing from Karolinska Development
STOCKHOLM, SWEDEN – March 31 2025: Modus Therapeutics Holding AB (“Modus”) today announces that the company has secured access to bridge financing of up to SEK 5.0 million from its largest shareholder, Karolinska Development AB. The financing enables Modus to maintain strong operational momentum in its ongoing Phase IIa study targeting anemia in chronic kidney disease (CKD).
John Öhd, CEO of Modus Therapeutics, commented:
“We are grateful for the continued support from our long-term investor Karolinska Development. This bridge financing is an important step in ensuring the progress of our clinical program, with current focus on completing Part 1 of our Phase IIa CKD study and preparing for Part 2. In parallel, we continue to actively evaluate options for long-term financing.”
For more information on Modus Therapeutics, please contact:
John Öhd, CEO, Modus Therapeutics
Phone: +46 (0) 70 766 80 97
Email: john.ohd@modustx.com
This information is information that Modus Therapeutics Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-31 14:00 CEST.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se
About Modus Therapeutics and sevuparin
Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com.
Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.
